Taylor Mercado

Dietary puerarin supplementation alleviates oxidative stress in the small intestines.

PMID: Animals (Basel). 2020 Apr 7 ;10(4). Epub 2020 Apr 7. PMID: 32272553 Abstract Title: Dietary Puerarin Supplementation Alleviates Oxidative Stress in the Small Intestines of Diquat-Challenged Piglets. Abstract: This study was conducted to demonstrate that dietary puerarin supplementation alleviates oxidative stress in the small intestine of diquat-challenged piglets. The results showed that puerarin administration …

Continue reading “Dietary puerarin supplementation alleviates oxidative stress in the small intestines.”

These finding highlights the potential value of puerarin developing as an anti-diabetic agent.

PMID: Phytomedicine. 2020 Apr 25 ;70:153222. Epub 2020 Apr 25. PMID: 32361558 Abstract Title: Puerarin ameliorates hyperglycemia in HFD diabetic mice by promotingβ-cell neogenesis via GLP-1R signaling activation. Abstract: BACKGROUND: Diabetes is characterized byβ-cell loss and dysfunction. A strategy for diabetes treatment is to promote new β-cell formation. Puerarin is an isoflavone from the root …

Continue reading “These finding highlights the potential value of puerarin developing as an anti-diabetic agent.”

Effects of puerarin on the pharmacokinetics of astragaloside IV in rats and its potential mechanism

PMID: Pharm Biol. 2020 Dec ;58(1):328-332. PMID: 32356474 Abstract Title: Effects of puerarin on the pharmacokinetics of astragaloside IV in rats and its potential mechanism. Abstract: Puerarin and astragaloside IV (AS-IV) are sometimes used together for the treatment of disease in Chinese clinics, however, the drug-drug interaction between puerarin and AS-IV is still unknown.This study …

Continue reading “Effects of puerarin on the pharmacokinetics of astragaloside IV in rats and its potential mechanism”

Astragaloside IV protects guman cardiomyocytes from hypoxia/reoxygenation injury by regulating miR-101a

PMID: Mol Cell Biochem. 2020 May 11. Epub 2020 May 11. PMID: 32394311 Abstract Title: Astragaloside IV protects human cardiomyocytes from hypoxia/reoxygenation injury by regulating miR-101a. Abstract: Astragaloside IV (AS/IV) is one of the extracted components from the traditional Chinese medicine Astragalus which has been demonstrated to have potential capacity for anti-inflammation activity and for …

Continue reading “Astragaloside IV protects guman cardiomyocytes from hypoxia/reoxygenation injury by regulating miR-101a”

Astragaloside IV ameliorates radiation-induced senescence via antioxidative mechanism.

PMID: J Pharm Pharmacol. 2020 May 15. Epub 2020 May 15. PMID: 32412100 Abstract Title: Astragaloside IV ameliorates radiation-induced senescence via antioxidative mechanism. Abstract: OBJECTIVES: Ageing is a universal and gradual process of organ deterioration. Radiation induces oxidative stress in cells, which leads to genetic damage and affects cell growth, differentiation and senescence. Astragaloside (AS)-IV …

Continue reading “Astragaloside IV ameliorates radiation-induced senescence via antioxidative mechanism.”

Effect of astragaloside IV on cognitive dysfunction in rats with cerebrally infarcted.

PMID: Cell Mol Biol (Noisy-le-grand). 2020 May 15 ;66(2):87-92. Epub 2020 May 15. PMID: 32415932 Abstract Title: Effect of astragaloside IV on cognitive dysfunction in rats with cerebrally infarcted via TGF-β / Smad signaling pathway. Abstract: Cerebral infarction is an acute cerebrovascular disease caused by abnormal blood circulation in the brain. In the present study, …

Continue reading “Effect of astragaloside IV on cognitive dysfunction in rats with cerebrally infarcted.”

Astragaloside IV suppresses development of hepatocellular carcinoma.

PMID: Environ Toxicol Pharmacol. 2020 Apr 25 ;78:103397. Epub 2020 Apr 25. PMID: 32417721 Abstract Title: Astragaloside IV suppresses development of hepatocellular carcinoma by regulating miR-150-5p/β-catenin axis. Abstract: Hepatocellular carcinoma (HCC), a common malignant tumor, has been regarded as a leading cause of cancer-related deaths globally. Astragaloside IV (AS-IV) was reported to participate in the …

Continue reading “Astragaloside IV suppresses development of hepatocellular carcinoma.”

Astragaloside IV promotes cerebral protection following angiogenesis and ischemic brain injury.

PMID: Restor Neurol Neurosci. 2020 May 12. Epub 2020 May 12. PMID: 32417803 Abstract Title: Astragaloside IV regulates the HIF/VEGF/Notch signaling pathway through miRNA-210 to promote angiogenesis after ischemic stroke. Abstract: BACKGROUND: Astragaloside IV (AS-IV) is one of the main active ingredients of Astragalusmembranaceus. Studies have shown that AS-IV stimulates angiogenesis, including cell proliferation, migration, …

Continue reading “Astragaloside IV promotes cerebral protection following angiogenesis and ischemic brain injury.”

The regulated profile of noncoding RNAs associated with inflammation by tanshinone IIA on atherosclerosis.

PMID: J Leukoc Biol. 2020 Apr 26. Epub 2020 Apr 26. PMID: 32337768 Abstract Title: The regulated profile of noncoding RNAs associated with inflammation by tanshinone IIA on atherosclerosis. Abstract: Atherosclerosis (AS) is the principal cause of heart attack, sudden cardiac death, stroke, and necrosis of the extremities, in which significant changes in gene expression …

Continue reading “The regulated profile of noncoding RNAs associated with inflammation by tanshinone IIA on atherosclerosis.”

Improved tendon healing by a combination of tanshinone IIA and miR-29b inhibitor treatment.

PMID: Int J Med Sci. 2020 ;17(8):1083-1094. Epub 2020 Apr 27. PMID: 32410838 Abstract Title: Improved tendon healing by a combination of Tanshinone IIA and miR-29b inhibitor treatment through preventing tendon adhesion and enhancing tendon strength. Abstract: : Despite significant advances in the materials and methods development used in surgical repair and postoperative rehabilitation, the …

Continue reading “Improved tendon healing by a combination of tanshinone IIA and miR-29b inhibitor treatment.”